Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

The molecular content that is passed from one cell to adjacent cells of the microenvironment ... make it possible to experimentally characterize exosomes. Miltenyi Biotec's new MACSPlex Exosome kit, ...

German biotechnology company Miltenyi Biotec has said that its CAR-T therapy ... The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

The option, which was part of a broader deal, gave BioNTech a chance to co-develop the cell therapy in return for an upfront fee and milestones. Building on its autologous CD19 CAR-T cell therapy ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.